Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Colorcon
Moodys
Cipla
AstraZeneca
Fuji
Merck
Dow
Deloitte
Fish and Richardson

Generated: October 23, 2017

DrugPatentWatch Database Preview

ULTRAM Drug Profile

« Back to Dashboard

What is the patent landscape for Ultram, and when can generic versions of Ultram launch?

Ultram is a drug marketed by Janssen Pharms and Valeant Pharms and is included in two NDAs. There is one patent protecting this drug and three Paragraph IV challenges.

The generic ingredient in ULTRAM is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Sixty-six suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.

Summary for Tradename: ULTRAM

US Patents:1
Applicants:2
NDAs:2
Suppliers / Packagers: see list3
Bulk Api Vendors: see list28
Clinical Trials: see list16
Patent Applications: see list1,269
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ULTRAM at DailyMed

Pharmacology for Tradename: ULTRAM

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
ULTRAM
tramadol hydrochloride
TABLET;ORAL020281-002Mar 3, 1995ABRXYesYes► Subscribe► SubscribeY► Subscribe
Valeant Pharms
ULTRAM ER
tramadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL021692-002Sep 8, 2005DISCNYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
ULTRAM
tramadol hydrochloride
TABLET;ORAL020281-001Mar 3, 1995DISCNNoNo► Subscribe► SubscribeY► Subscribe
Valeant Pharms
ULTRAM ER
tramadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL021692-001Sep 8, 2005DISCNYesNo► Subscribe► Subscribe► Subscribe
Valeant Pharms
ULTRAM ER
tramadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL021692-003Sep 8, 2005DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ULTRAM

Drugname Dosage Strength RLD Submissiondate
tramadol hydrochlorideExtended-release Tablets300 mgUltram ER9/25/2007
tramadol hydrochlorideExtended-release Tablets200 mgUltram ER3/28/2007
tramadol hydrochlorideExtended-release Tablets100 mgUltram ER1/8/2007
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Federal Trade Commission
Novartis
Chubb
Chinese Patent Office
Teva
Dow
Harvard Business School
McKinsey
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot